RBL1 (Ab-369) polyclonal Antibody | BS65104

RBL1 (Ab-369) polyclonal Antibody | BS65104 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse

Application: WB,IHC-p,IF (paraffin section),ELISA

Application Range: Immunohistochemistry: 1/100 - 1/300. ELISA: 1/5000. Not yet tested in other applications.

Background: RB transcriptional corepressor like 1 (RBL1) Homo sapiens The protein encoded by this gene is similar in sequence and possibly function to the product of the retinoblastoma 1 (RB1) gene. The RB1 gene product is a tumor suppressor protein that appears to be involved in cell cycle regulation, as it is phosphorylated in the S to M phase transition and is dephosphorylated in the G1 phase of the cell cycle. Both the RB1 protein and the product of this gene can form a complex with adenovirus E1A protein and SV40 large T-antigen, with the SV40 large T-antigen binding only to the unphosphorylated form of each protein. In addition, both proteins can inhibit the transcription of cell cycle genes containing E2F binding sites in their promoters. Due to the sequence and biochemical similarities with the RB1 protein, it is thought that the protein encoded by this gene may also be a tumor suppressor. Two transcript variants encoding different isoforms hav

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Phospho-p107 (T369) Polyclonal Antibody detects endogenous levels of p107 protein only when phosphorylated at T369.

Molecular Weight: /

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: RBL1; Retinoblastoma-like protein 1; 107 kDa retinoblastoma-associated protein; p107; pRb1

Immunogen: The antiserum was produced against synthesized peptide derived from human RBL1 around the phosphorylation site of Thr369. AA range:335-384

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Pathway: